Comparative Pharmacology
Head-to-head clinical analysis: ANDROID F versus TESTODERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID F versus TESTODERM.
ANDROID-F vs TESTODERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.
Testosterone replacement therapy: binds to androgen receptors, activating gene transcription for protein synthesis and muscle growth.
Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.
One to two 2.5 mg or 5 mg patches applied to clean, dry, intact skin of the back, abdomen, upper arms, or thighs once daily (approximately every 24 hours).
None Documented
None Documented
2.5-3.5 hours (terminal half-life); oral administration may require multiple daily doses for stable levels.
Terminal elimination half-life is approximately 10-100 minutes for free testosterone in plasma; for total testosterone (including bound), the apparent half-life ranges from 2-4 hours after transdermal application, with significant interindividual variability.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); small amount biliary/fecal.
Primarily renal (approximately 90% as glucuronide and sulfate conjugates, <10% as unchanged testosterone); about 6% is excreted in feces via biliary elimination.
Category C
Category C
Androgen/Estrogen Combination
Androgen